4.7 Letter

Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases

Journal

ANNALS OF THE RHEUMATIC DISEASES
Volume 80, Issue 10, Pages 1357-+

Publisher

BMJ PUBLISHING GROUP
DOI: 10.1136/annrheumdis-2021-220604

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available